Portal de Periódicos da CAPES

Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies

2021; Ferrata Storti Foundation; Volume: 107; Issue: 3 Linguagem: Inglês

10.3324/haematol.2021.279216

1592-8721

Ronit Gurion, Uri Rozovski, Gilad Itchaki, Anat Gafter‐Gvili, Chiya Leibovitch, Pia Raanani, Haim Ben‐Zvi, Moran Szwarcwort, Mor Taylor-Abigadol, Eldad J. Dann, Nurit Horesh, Tsofia Inbar, Inna Tzoran, Noa Lavi, Riva Fineman, Shimrit Ringelstein‐Harlev, Netanel A. Horowitz,

COVID-19 and healthcare impacts

Patients with lymphoma, especially those treated with anti-CD20 monoclonal antibodies, suffer high COVID-19-associated morbidity and mortality. The goal of this study was to assess the ability of lymphoma patients to generate a sufficient humoral response after two injections of BNT162b2 Pfizer vaccine and to identify factors influencing the response. Antibody titers were measured with the SARS-CoV-2 IgG II Quant (Abbott ) assay in blood samples drawn from lymphoma patients 4 2 weeks after the second dose of vaccine. The cutoff for a positive response was set at 50 AU/mL. Positive serological responses were observed in 51% of the 162 patients enrolled in this cross-sectional study. In a multivariate analysis, an interval of <12 months between the last anti-CD20 monoclonal antibody dose and the second vaccine dose (odds ratio=31.3 [95% confidence interval: 8.4-116.9], P 1 year after this therapy. The latter percentage was equal to that of patients never exposed to monoclonal antibodies. In conclusion, lymphoma patients, especially those recently treated with anti- CD20 monoclonal antibodies, fail to develop sufficient humoral response to BNT162b2 vaccine. While a serological response is not the only predictor of immunity, its low level could make this population more vulnerable to COVID-19, which implies the need for a different vaccination schedule for such patients.